XML 55 R44.htm IDEA: XBRL DOCUMENT v3.20.2
SEGMENT INFORMATION (Tables)
 9 Months Ended
Jul. 31, 2020
Segment Reporting [Abstract]  
Segment Profitability and Segment Assets
The following table reflects segment assets under our management reporting system. Segment assets include allocations of corporate assets, goodwill, net other intangibles and other assets. Unallocated assets primarily consist of cash, cash equivalents, the valuation allowance relating to deferred tax assets and other assets.  
 
July 31,
2020
 
October 31,
2019
 
(in millions)
Segment Assets:
 
 
 
Life Sciences and Applied Markets
$
3,121

 
$
3,202

Diagnostics and Genomics
2,518

 
2,620

Agilent CrossLab
1,361

 
1,331

Total segment assets
$
7,000

 
$
7,153


The profitability of each of the segments is measured after excluding transformational initiatives, acquisition and integration costs, investment gains and losses, interest income, interest expense, acquisition and integration costs, non-cash amortization, impairment of acquisition-related intangibles and other items as noted in the reconciliations below:
 
Three Months Ended
 
Nine Months Ended
 
July 31,
 
July 31,
 
2020
 
2019
 
2020
 
2019
 
(in millions)
Net Revenue:
 
 
 
 
 
 
 
Life Sciences and Applied Markets
$
557

 
$
544

 
$
1,721

 
$
1,680

Diagnostics and Genomics
241

 
263

 
753

 
752

Agilent CrossLab
463

 
467

 
1,382

 
1,364

Total net revenue
$
1,261

 
$
1,274

 
$
3,856

 
$
3,796

 
 
 
 
 
 
 
 
Segment Income From Operations:


 


 
 
 
 
Life Sciences and Applied Markets
$
126

 
$
118

 
$
382

 
$
384

Diagnostics and Genomics
41

 
50

 
132

 
132

Agilent CrossLab
132

 
122

 
373

 
342

Total segment income from operations
$
299

 
$
290

 
$
887

 
$
858
Reconciliation of segment results to total enterprise results
The following table reconciles segment income from operations to Agilent’s total enterprise income before taxes: 
 
Three Months Ended
 
Nine Months Ended
 
July 31,
 
July 31,
 
2020
 
2019
 
2020
 
2019
 
(in millions)
Total segment income from operations
$
299

 
$
290

 
$
887

 
$
858

Transformational initiatives
(13
)
 
(11
)
 
(41
)
 
(25
)
Amortization of intangible assets related to business combinations
(45
)
 
(25
)
 
(139
)
 
(79
)
Acquisition and integration costs
(9
)
 
(12
)
 
(33
)
 
(32
)
Asset impairment
—

 
—

 
(99
)
 
—

Acceleration of share-based compensation expense
(1
)
 
—

 
(1
)
 
—

NASD site costs
—

 
(6
)
 
—

 
(12
)
Special compliance costs
—

 
(1
)
 
—

 
(2
)
Other(1)
(1
)
 
(10
)
 
(27
)
 
(17
)
Interest income
1

 
10

 
7

 
30

Interest expense
(19
)
 
(18
)
 
(59
)
 
(53
)
Other income (expense), net (2)
7

 
5

 
64

 
20

Income before taxes, as reported
$
219

 
$
222

 
$
559

 
$
688


(1) The other category primarily includes the legal costs related to a claim we pursued against Twist Bioscience Corporation
in addition to other miscellaneous adjustments.
(2) Other income (expense), net for the nine months ended July 31, 2020 includes the settlement of the legal claim against
Twist Bioscience Corporation.